The health insurance companies involved pursue the goal of working with all suitable pharmaceutical entrepreneurs

to conclude discount agreements according to § 130a (8) SGB V for the active substance mentioned in the respective lot. The contract is concluded

within the framework of the open house biology process of health insurance companies:

Individual negotiations on contract content are not conducted, uniform conditions apply. The

Health insurance companies do not assure individual contracting partners exclusivity. The contract period is maximum

12 months beginning with 01.01.2022 (sometimes different starts of individual cash registers result from the details for the respective lot). The contract ends no later than December 31, 2022, regardless of the date of conclusion of the contract. All further information can be found in the participation and contract documents

Remove.

It is possible to join this open house biological process at any time within the contract period.

A contract is concluded with all pharmaceutical companies that meet the requirements of Annex 4 to the contract (self-declaration for approval and for the company) and who confirm this in electronic form in accordance with § 126a BGB.

This publication does not concern the award of a public contract within the meaning of the Procurement Directive (2014/24/EC) or antitrust procurement law. In the interest of providing interested parties with the broadest possible information

pharmaceutical entrepreneur, this announcement is made in

Supplement to the Official Journal of the European Union. The procedure name “open procedure” used in the context of this publication text according to point IV.1.1) and the indication of the award criteria according to point II.2.5) are due to the specifications of the announcement form and have no further meaning. This, as well as with the use of the medium “TED”, is not subject to any submission to public procurement regulations whose validity is not mandatory by law or procurement regulations.

It is possible to join this open house biological process at any time within the contract period.

A contract is concluded with all pharmaceutical companies that meet the requirements of Annex 4 to the contract (self-declaration for approval and for the company) and who confirm this in electronic form in accordance with § 126a BGB.

This publication does not concern the award of a public contract within the meaning of the Procurement Directive (2014/24/EC) or antitrust procurement law. In the interest of providing interested parties with the broadest possible information

pharmaceutical entrepreneur, this announcement is made in

Supplement to the Official Journal of the European Union. The procedure name “open procedure” used in the context of this publication text according to point IV.1.1) and the indication of the award criteria according to point II.2.5) are due to the specifications of the announcement form and have no further meaning. This, as well as with the use of the medium “TED”, is not subject to any submission to public procurement regulations whose validity is not mandatory by law or procurement regulations.

It is possible to join this open house biological process at any time within the contract period.

A contract is concluded with all pharmaceutical companies that meet the requirements of Annex 4 to the contract (self-declaration for approval and for the company) and who confirm this in electronic form in accordance with § 126a BGB.

This publication does not concern the award of a public contract within the meaning of the Procurement Directive (2014/24/EC) or antitrust procurement law. In the interest of providing interested parties with the broadest possible information

pharmaceutical entrepreneur, this announcement is made in

Supplement to the Official Journal of the European Union. The procedure name “open procedure” used in the context of this publication text according to point IV.1.1) and the indication of the award criteria according to point II.2.5) are due to the specifications of the announcement form and have no further meaning. This, as well as with the use of the medium “TED”, is not subject to any submission to public procurement regulations whose validity is not mandatory by law or procurement regulations.

It is possible to join this open house biological process at any time within the contract period.

A contract is concluded with all pharmaceutical companies that meet the requirements of Annex 4 to the contract (self-declaration for approval and for the company) and who confirm this in electronic form in accordance with § 126a BGB.

This publication does not concern the award of a public contract within the meaning of the Procurement Directive (2014/24/EC) or antitrust procurement law. In the interest of providing interested parties with the broadest possible information

pharmaceutical entrepreneur, this announcement is made in

Supplement to the Official Journal of the European Union. The procedure name “open procedure” used in the context of this publication text according to point IV.1.1) and the indication of the award criteria according to point II.2.5) are due to the specifications of the announcement form and have no further meaning. This, as well as with the use of the medium “TED”, is not subject to any submission to public procurement regulations whose validity is not mandatory by law or procurement regulations.

It is possible to join this open house biological process at any time within the contract period.

A contract is concluded with all pharmaceutical companies that meet the requirements of Annex 4 to the contract (self-declaration for approval and for the company) and who confirm this in electronic form in accordance with § 126a BGB.

This publication does not concern the award of a public contract within the meaning of the Procurement Directive (2014/24/EC) or antitrust procurement law. In the interest of providing interested parties with the broadest possible information

pharmaceutical entrepreneur, this announcement is made in

Supplement to the Official Journal of the European Union. The procedure name “open procedure” used in the context of this publication text according to point IV.1.1) and the indication of the award criteria according to point II.2.5) are due to the specifications of the announcement form and have no further meaning. This, as well as with the use of the medium “TED”, is not subject to any submission to public procurement regulations whose validity is not mandatory by law or procurement regulations.

It is possible to join this open house biological process at any time within the contract period.

A contract is concluded with all pharmaceutical companies that meet the requirements of Annex 4 to the contract (self-declaration for approval and for the company) and who confirm this in electronic form in accordance with § 126a BGB.

This publication does not concern the award of a public contract within the meaning of the Procurement Directive (2014/24/EC) or antitrust procurement law. In the interest of providing interested parties with the broadest possible information

pharmaceutical entrepreneur, this announcement is made in

Supplement to the Official Journal of the European Union. The procedure name “open procedure” used in the context of this publication text according to point IV.1.1) and the indication of the award criteria according to point II.2.5) are due to the specifications of the announcement form and have no further meaning. This, as well as with the use of the medium “TED”, is not subject to any submission to public procurement regulations whose validity is not mandatory by law or procurement regulations.

It is possible to join this open house biological process at any time within the contract period.

A contract is concluded with all pharmaceutical companies that meet the requirements of Annex 4 to the contract (self-declaration for approval and for the company) and who confirm this in electronic form in accordance with § 126a BGB.

This publication does not concern the award of a public contract within the meaning of the Procurement Directive (2014/24/EC) or antitrust procurement law. In the interest of providing interested parties with the broadest possible information

pharmaceutical entrepreneur, this announcement is made in

Supplement to the Official Journal of the European Union. The procedure name “open procedure” used in the context of this publication text according to point IV.1.1) and the indication of the award criteria according to point II.2.5) are due to the specifications of the announcement form and have no further meaning. This, as well as with the use of the medium “TED”, is not subject to any submission to public procurement regulations whose validity is not mandatory by law or procurement regulations.